HealthEquity HQY 深 滬
等待開盤 09-24 09:30:00 美东时间
90.39
-1.360
-1.48%
華盛通- 最 高92.02
- 今 開91.35
- 成交量 90.01万股
- 最 低 90.20
- 昨 收 91.75
- 總市值 74.77亿
- 52周最高 107.62
- 市盈率 靜 36.74
- 換手率 1.09%
- 52周最低 72.76
- 委 比 90.06%
- 總股本 8271.53万
- 歷史最高 116.65
- 量 比 1.00
- 振 幅 1.98%
- 歷史最低 15.80
- 每 手 1
- 風險率 8.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 奈飞遭看淡至57美元！现价仍有两成下行空间；Xenon制药遭多家机构降目标价，最低看至46美元
今日重点评级关注：康托·菲茨杰拉德：维持Abeona Therapeutics"超配"评级，目标价从28美元升至30美元；HC Wainwright & Co.：维持Oculis Holding"买入"评级，目标价从26美元升至39美元
09-21 16:25
Barclays Maintains Overweight on HealthEquity, Raises Price Target to $115
Barclays analyst Peter Warendorf maintains HealthEquity (NASDAQ:HQY) with a Overweight and raises the price target from $110 to $115.
09-18 21:07
美股大行评级 | Affirm、GitLab获多家大行上调目标价；Attovia获大摩、花旗首予买入评级
今日重点评级关注：杰富瑞：维持拜玛林制药"买入"评级，目标价从104美元升至105美元；RBC Capital：维持Shift4 Payments"跑赢大市"评级，目标价从63美元升至67美元
09-01 08:37
美股大行评级 | 潜在涨幅768.26%！Ascendiant Capital维持RenovoRx(RNXT)"买入"评级，目标价上调至14.5美元
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从14美元升至14.5美元；HC Wainwright & Co.：维持Generate Biomedicines"买入"评级，目标价从25美元升至30美元
08-31 18:14
BTIG Reiterates Buy on HealthEquity, Maintains $115 Price Target
BTIG analyst David Larsen reiterates HealthEquity (NASDAQ:HQY) with a Buy and maintains $115 price target.
08-28 18:34
HealthEquity shares are trading lower after the company issued Q2 financial results. The company affirmed its FY27 adjusted EPS guidance with its midpoint below estimates.
HealthEquity shares are trading lower after the company issued Q2 financial results. The company affirmed its FY27 adjusted EPS guidance with its midpoint below estimates.
08-27 20:37
财报速睇 | HealthEquity 2026财年Q3营收3.51亿美元，同比增长7.6%；归母净利润0.66亿美元，同比增长9.7%
华盛资讯8月27日讯，HealthEquity公布2026财年Q3业绩，公司Q3营收3.51亿美元，同比增长7.6%，归母净利润0.66亿美元，同比增长9.7%。
08-27 20:17
HealthEquity Q2 Adj. EPS $1.24 Beats $1.19 Estimate, Sales $350.732M Beat $349.248M Estimate
HealthEquity (NASDAQ:HQY) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1.19 by 4.2 percent. This is a 14.81 percent increase over earnings of $1.08 per share from the same period last year. The company reported quarterly sales of $350.732 million which...
08-27 20:07
HealthEquity Affirms FY2027 Adj EPS Guidance of $4.66-$4.73 vs $4.72 Est; Raises FY2027 Sales Guidance from $1.410B-$1.420B to $1.411B-$1.421B vs $1.416B Est
HealthEquity (NASDAQ:HQY) affirms FY2027 Adj EPS guidance from $4.66-$4.73 to $4.66-$4.73 vs $4.72 analyst estimate. Raises FY2027 sales outlook from $1.410 billion-$1.420 billion to $1.411 billion-$1.421 billion vs $1.416 billion estimate.
08-27 20:06
HealthEquity (HQY) Fiscal Q2 2027 Earnings Call: Record 48% EBITDA Margin, Guidance Raised
HealthEquity’s fiscal Q2 2027 earnings call covered 8% revenue growth, a record 48% adjusted EBITDA margin, HSA momentum and higher full-year guidance.
08-27 20:01
